中药与天然产物抗癫痫的多靶点综述:神经元、胶质与炎症信号
该综述汇总15种代表性中药或天然代谢物在癫痫相关模型中的实验、临床与转化证据,将其映射至神经元兴奋性、海马脆弱性、小胶质细胞活化及MAPK、mTOR、TLR4/NF-κB等炎症通路,区分急性止惊、状态癫痫后神经保护与真正抗癫痫发生效应,指出临床前多靶点合理性但证据受模型与质量限制。
要点
- 临床前证据支持中药多靶点调控神经炎症与神经元-胶质稳态。
- 需区分急性止惊、状态癫痫后神经保护与疾病修饰效应。
- 现有证据多限于急性化学惊厥模型与预处理设计,临床验证不足。
核心结论
- 临床前数据支持中药与天然产物通过多靶点调控神经炎症和神经元-胶质稳态发挥抗癫痫潜力。
- 多数证据受限于急性化学惊厥模型、预处理设计及不完整的植物化学表征。
研究设计与样本
- 结构化叙述性检索与证据评价框架,纳入15种代表性中药或天然代谢物。
主要发现
- 文献将中药作用映射至神经元兴奋性、海马与内嗅区脆弱性、齿状回重塑、小胶质细胞活化、星形胶质细胞功能障碍、神经递质平衡、离子通道调控及MAPK、mTOR、PI3K/AKT/FoxO1、TLR4/NF-κB、Nrf2/HO-1、CREB等炎症信号通路。
- 综述区分了急性惊厥抑制、状态癫痫后神经保护与真正抗癫痫发生或疾病修饰效应。
关键数值与推荐
- 原文纳入15种代表性中药或天然代谢物进行证据评价。
临床怎么用
- 临床应认识到中药抗癫痫证据以临床前机制为主,不宜过度外推至临床疗效。
- 未来研究应优先采用分类学验证药材、化学表征制剂、慢性癫痫模型及随机试验。
局限性
- 多数证据限于急性化学惊厥模型与预处理设计。
- 植物或化学表征不完整,剂量报告不一,高质量临床验证有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Epilepsy is a chronic neurological disorder characterized by recurrent unprovoked seizures, substantial comorbidity, and persistent pharmacoresistance in approximately one-third of affected patients. Chinese medicinal materials, including botanical drugs, selected animal-derived medicinal materials, extracts, and defined natural metabolites, have long been used as adjunctive approaches for seizure-related disorders; however, their modern pharmacological evidence remains heterogeneous and is often interpreted too broadly. This critical review synthesizes experimental, clinical, and translational evidence on 15 representative Chinese medicinal materials or natural metabolites that have been investigated in epilepsy-related models. Using a structured narrative search and an evidence-appraisal framework, we map these materials to neuronal excitability, hippocampal and entorhinal vulnerability, dentate-gyrus remodeling, microglial activation, astrocyte dysfunction, neurotransmitter balance, ion-channel regulation, and inflammatory signaling pathways including MAPK, mTOR, PI3K/AKT/FoxO1, TLR4/NF-κB, Nrf2/HO-1, and CREB. We distinguish acute seizure suppression, neuroprotection after status epilepticus, and true anti-epileptogenic or disease-modifying effects. Overall, preclinical data support multi-target biological plausibility, particularly for regulation of neuroinflammation and neuron-glia homeostasis, but most evidence remains limited by acute chemoconvulsant models, pre-treatment designs, incomplete botanical or chemical characterization, variable dose reporting, and limited high-quality clinical validation. Future studies should prioritize taxonomically validated materials, chemically characterized preparations, clinically relevant chronic seizure models, standardized outcomes, pharmacokinetic and herb-drug interaction testing, and rigorously designed randomized trials.
引用
- Yan S, Li H, Liu Y, et al. Ethnopharmacological relevance of Chinese medicinal materials and natural products in epilepsy: a critical multi-target review integrating neurons, glia and inflammatory signaling. Front Pharmacol. 2026. PMID: 42428507. doi:10.3389/fphar.2026.1819195
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。